Skip to content

Search

Early life innate immune signatures of persistent food allergy

Early life innate immune dysfunction may represent a key immunological driver and predictor of persistent food allergy in childhood

Incidental inequity

Reporting incidental genomic findings requires various considerations. One of these is that 'the clinical validity and utility of variants should be known'.

Cellular and molecular mechanisms of vitamin D in food allergy

Epidemiological evidence from the past decade suggests a role of vitamin D in food allergy pathogenesis

Partnering with communities to reduce rheumatic heart disease in the Kimberley

The Kimberley has the highest rates of rheumatic heart disease (RHD) in Western Australia – but through the establishment of a new community-led, research-backed project known as END RHD Communities, there’s hope this will change.

Atopy-dependent and independent immune responses in the heightened severity of atopics to respiratory viral infections: Rat model studies

The co-exposure responses in the Th2high BN incorporated type I interferon/Th1, alternative macrophage activation/Th2 and Th17 signatures

Effects of human rhinovirus on epithelial barrier integrity and function in children with asthma

This study demonstrates novel intrinsic differences in tight junctions gene and protein expression between airway epithelial cells of children with and without asthma

The Ultra-High-Risk for psychosis groups: Evidence to maintain the status quo

Our findings demonstrate that Ultra-High-Risk groups evidence a similar clinical risk profile when we expand this beyond transition to psychosis

Elucidating the genetic architecture of Adams-Oliver syndrome in a large European cohort

The purpose of this study was therefore to comprehensively examine the genetic architecture of Adams-Oliver syndrome in an extensive cohort

Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia

Our population-based cohort study demonstrates that >90% coverage in the first year of a universal 3 + 0 PCV program provided high population-level protection